The Duality of STAT2 Mediated Type I Interferon Signaling in the Tumor Microenvironment and Chemoresistance

Overview

Journal Cytokine

Specialties Allergy & Immunology
Biology

Date 2022 Nov 3

PMID 36327541

Authors

Jorge Canar

Kennedy Darling

Ryan Dadey

Ana M Gamero

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment consists of tumor cells, extracellular matrix, blood vessels, and non-tumor cells such as fibroblasts and immune cells. Crosstalk among components of this cellular ecosystem can transform non-malignant cells and promote tumor invasion and metastasis. Evidence is accumulating that the transcription factor STAT2, a downstream effector of type I interferon (IFN-I) signaling, can either inhibit or promote tumorigenesis depending on the unique environment presented by each type of cancer. STAT2 has long been associated with the canonical JAK/STAT pathway involved in various biological processes including reshaping of the tumor microenvironment and in antitumor immunity. This dichotomous tendency of STAT2 to both inhibit and worsen tumor formation makes the protein a curious, and yet relatively ill-defined player in many cancer pathways involving IFN-I. In this review, we discuss the role of STAT2 in contributing to either a tumorigenic or anti-tumorigenic microenvironment as well as chemoresistance.

Citing Articles

Functional Involvement of Signal Transducers and Activators of Transcription in the Pathogenesis of Influenza A Virus.

Liu S, Qiu F, Gu R, Xu E Int J Mol Sci. 2025; 25(24.

PMID: 39769350 PMC: 11677356. DOI: 10.3390/ijms252413589.

The Protective Effects of an Aged Black Garlic Water Extract on the Prostate.

Libero M, Montero-Hidalgo A, Recinella L, Luque R, Generali D, Acquaviva A Nutrients. 2024; 16(17).

PMID: 39275340 PMC: 11396974. DOI: 10.3390/nu16173025.

Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.

Wang W, Lopez McDonald M, Hariprasad R, Hamilton T, Frank D Cancers (Basel). 2024; 16(7).

PMID: 38611065 PMC: 11011165. DOI: 10.3390/cancers16071387.

STAT2 Controls Colorectal Tumorigenesis and Resistance to Anti-Cancer Drugs.

Chiriac M, Hracsko Z, Becker C, Neurath M Cancers (Basel). 2023; 15(22).

PMID: 38001683 PMC: 10670206. DOI: 10.3390/cancers15225423.

References

Weichselbaum R, Ishwaran H, Yoon T, Nuyten D, Baker S, Khodarev N . An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008; 105(47):18490-5. PMC: 2587578. DOI: 10.1073/pnas.0809242105. View

Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu E . Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat Commun. 2021; 12(1):5866. PMC: 8497482. DOI: 10.1038/s41467-021-26112-2. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Wang J, Pham-Mitchell N, Schindler C, Campbell I . Dysregulated Sonic hedgehog signaling and medulloblastoma consequent to IFN-alpha-stimulated STAT2-independent production of IFN-gamma in the brain. J Clin Invest. 2003; 112(4):535-43. PMC: 171394. DOI: 10.1172/JCI18637. View

Johnson D, OKeefe R, Grandis J . Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018; 15(4):234-248. PMC: 5858971. DOI: 10.1038/nrclinonc.2018.8. View

He Y, Wang L, Wei T, Xiao Y, Sheng H, Su H . FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest. 2021; 131(14). PMC: 8279591. DOI: 10.1172/JCI147025. View

Brockwell N, Parker B . Tumor inherent interferons: Impact on immune reactivity and immunotherapy. Cytokine. 2018; 118:42-47. DOI: 10.1016/j.cyto.2018.04.006. View

cermak V, Gandalovicova A, Merta L, Harant K, Rosel D, Brabek J . High-throughput transcriptomic and proteomic profiling of mesenchymal-amoeboid transition in 3D collagen. Sci Data. 2020; 7(1):160. PMC: 7253430. DOI: 10.1038/s41597-020-0499-2. View

House I, Savas P, Lai J, Chen A, Oliver A, Teo Z . Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res. 2019; 26(2):487-504. DOI: 10.1158/1078-0432.CCR-19-1868. View

10.

Pankova K, Rosel D, Novotny M, Brabek J . The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci. 2009; 67(1):63-71. PMC: 2801846. DOI: 10.1007/s00018-009-0132-1. View

11.

Mazewski C, Perez R, Fish E, Platanias L . Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. Front Immunol. 2020; 11:606456. PMC: 7719805. DOI: 10.3389/fimmu.2020.606456. View

12.

Gardner A, Ruffell B . Dendritic Cells and Cancer Immunity. Trends Immunol. 2016; 37(12):855-865. PMC: 5135568. DOI: 10.1016/j.it.2016.09.006. View

13.

Katlinski K, Gui J, Katlinskaya Y, Ortiz A, Chakraborty R, Bhattacharya S . Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017; 31(2):194-207. PMC: 5313042. DOI: 10.1016/j.ccell.2017.01.004. View

14.

Wang D, Fu Z, Gao L, Zeng J, Xiang Y, Zhou L . Increased IRF9-STAT2 Signaling Leads to Adaptive Resistance toward Targeted Therapy in Melanoma by Restraining GSDME-Dependent Pyroptosis. J Invest Dermatol. 2022; 142(9):2476-2487.e9. DOI: 10.1016/j.jid.2022.01.024. View

15.

Xu J, Lee M, Chakhtoura M, Green B, Kotredes K, Chain R . STAT2 Is Required for TLR-Induced Murine Dendritic Cell Activation and Cross-Presentation. J Immunol. 2016; 197(1):326-36. PMC: 4912940. DOI: 10.4049/jimmunol.1500152. View

16.

Slaton J, Karashima T, Perrotte P, Inoue K, Kim S, Izawa J . Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res. 2001; 7(9):2840-53. View

17.

Davar D, Wang H, Chauvin J, Pagliano O, Fourcade J, Ka M . Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol. 2018; :JCO1800632. PMC: 6286160. DOI: 10.1200/JCO.18.00632. View

18.

Critchley-Thorne R, Simons D, Yan N, Miyahira A, Dirbas F, Johnson D . Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009; 106(22):9010-5. PMC: 2690021. DOI: 10.1073/pnas.0901329106. View

19.

Arico E, Castiello L, Capone I, Gabriele L, Belardelli F . Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications. Cancers (Basel). 2019; 11(12). PMC: 6966569. DOI: 10.3390/cancers11121943. View

20.

Duncan C, Thompson B, Chen R, Rice G, Gothe F, Young D . Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in . Sci Immunol. 2019; 4(42). PMC: 7115903. DOI: 10.1126/sciimmunol.aav7501. View